FindTrial
Sign In

17-N-allylamino-17-demethoxygeldanamycin/bortezomib

DRUG2 trials

Sponsors

National Cancer Institute (NCI)

Conditions

Adult Lymphocyte Depletion Hodgkin LymphomaAdult Mixed Cellularity Hodgkin LymphomaAdult Nodular Sclerosis Hodgkin LymphomaRecurrent Adult Hodgkin LymphomaRefractory Chronic Lymphocytic LeukemiaRefractory Multiple MyelomaStage III Multiple MyelomaStage IV Chronic Lymphocytic Leukemia

Phase 1

Sorafenib and Bortezomib in Treating Patients With Advanced Cancer
CompletedNCT00303797
National Cancer Institute (NCI)Refractory Chronic Lymphocytic Leukemia, Refractory Multiple Myeloma, Stage III Multiple Myeloma +2
Start: 2005-12-31Updated: 2013-03-19

Phase 2

Bortezomib in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma
CompletedNCT00082966
National Cancer Institute (NCI)Adult Lymphocyte Depletion Hodgkin Lymphoma, Adult Mixed Cellularity Hodgkin Lymphoma, Adult Nodular Sclerosis Hodgkin Lymphoma +1
Start: 2004-03-31Updated: 2015-12-04